OpGen Announces Strategic Collaboration with IQT
News May 01, 2012
The technology is being developed for the Department of Homeland Security Science and Technology Directorate (DHS S&T), an IQT customer agency, and the National Bioforensic Analysis Center, a DHS S&T laboratory.
"OpGen is the leader in developing Whole Genome Mapping technologies for use with next generation sequencing (NGS) analysis pipelines," said Simon Davidson, partner on IQT's Investments team. "The company is the ideal partner to develop new software for high performance microbial data analysis to increase the speed and accuracy of analyzing samples from different sources to detect potential bio-threat organisms that may pose a danger to public health."
The enhanced application will automate the generation of OpGen's Whole Genome Maps for use in high-throughput genomic assembly and analysis pipelines. The suite of applications in the pipeline will automatically align DNA sequence data to a map of the entire genome and recommend the most accurate finished sequences derived from the highest confidence alignments. The software system is being developed for use with computer clusters and cloud computing to provide rapid, accurate, reproducible and standardized assembly of microbial genome sequences.
"Combining OpGen's Whole Genome Maps with next-generation sequencing saves finishing cost and time while significantly increasing accuracy," said Richard Moore, M.D., Ph.D., chief scientific officer of OpGen. "The additional automation to be provided by this collaboration will make the finishing process much more efficient. In addition, this project will enable more flexible configuration of the Argus(R) system allowing us to better meet the analysis needs of our customers."
"We are pleased to partner with IQT to develop innovative tools for high-throughput, whole genome, sequence analysis," said Douglas White, chief executive officer of OpGen. "Our ultimate goal is to develop systems, databases and services that simplify and standardize processes and information to enable the broader adoption of next-generation sequencing and Whole Genome Mapping for practical application in the biodefense, public health and clinical markets."
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Study Indicates 75% of Human Genome is Non-functionalNews
An evolutionary biologist at the University of Houston has published new calculations that indicate no more than 25 percent of the human genome is functional.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018